欧美日韩国产免费,欧美xxxx做受欧美88bbw,韩国久久久久久

2020年8月27～29日，第55屆歐洲肝臟研究學(xué)會年會（EASL2020）暨國際肝臟會議（TheDigitalInternationalLiverCongress?2020，ILC2020）將在歐洲最大的城市——英國·倫敦盛大召開。

既往歐洲國際肝病大會現(xiàn)場都會匯集來自世界各地的專家，借此了解肝臟研究的最新進(jìn)展。與以往不同的是，鑒于COVID-19大流行的影響，今年大會完全改為線上舉行。

今年大會共收集了來自55個國家專家學(xué)者的研究摘要，其中1470+多篇原創(chuàng)研究成果將在壁報和視頻展示。依照慣例，今年篩選出8項(xiàng)最新突破研究和13項(xiàng)重磅研究分別在最新突破專題（LateBreaker）和全體大會（Generalsession）由團(tuán)隊(duì)代表進(jìn)行口頭報告。重磅研究見下：

GS01苯扎貝特（Bezafibrate）聯(lián)合治療可提高原發(fā)性膽管炎無肝移植患者的存活率：一項(xiàng)日本全國性隊(duì)列研究

GS01Bezafibrateadd-ontherapyimproveslivertransplantation-freesurvivalinpatientswithprimarybiliarycholangitis:aJapanesenationwidecohortstudy

AtsushiTanaka,JapanCo-author:ChristopheCorpechot

27August202013:15-13:30

GS02糞便亞基因組中的毒性相關(guān)基因與酒精性肝炎患者死亡率相關(guān)

GS02Virulence-relatedgenesinfaecalmetagenomesassociatedwithmortalityinpatientswithalcoholichepatitis

SonjaLang,UnitedStatesCo-author:BerndSchnabl

27August202013:30-13:45

GS03端粒相關(guān)基因突變患者的肝臟受累：患病率、臨床、影像學(xué)、病理學(xué)特征、轉(zhuǎn)歸和危險因素

GS03Liverinvolvementinpatientswithtelomere-relatedgenesmutations:prevalence,clinical,radiological,pathologicalfeatures,outcomeandriskfactors

SabrinaSIDALI,FranceCo-author:AuréliePlessier

27August202013:45-14:00

GS04腸道微生物群通過促進(jìn)TLR4依賴的單核細(xì)胞髓源性抑制細(xì)胞的增殖來促進(jìn)肝癌發(fā)生

GS04GutmicrobiotadriveshepatocarcinogenesisbypromotingTLR4-dependentexpansionofmonocyticmyeloid-derivedsuppressorcells

KaiMarkusSchneider,GermanyCo-author:AntjeMohs

27August202014:00-14:15

GS05歐洲國家器官儲運(yùn)組織終末期肝病鈉評分的模型驗(yàn)證

GS05ValidationoftheModelforEnd-stageLiverDiseasesodiumscorefortheEurotransplantregion.

BenGoudsmit,NetherlandsCo-author:BartVanHoek

27August202014:15-14:30

GS06一項(xiàng)隨機(jī)、多中心、雙盲、安慰劑對照試驗(yàn)：左旋肉堿對肝硬化患者和隱性肝性腦病患者生活質(zhì)量的影響

GS06Arandomised,multi-centre,double-blinded,placebocontrolled,investigator-initiatedtrialtoassesstheimpactofL-carnitineadministrationonqualityoflifeincirrhosispatientsandcoverthepaticencephalopathy

EileenYoon,Korea,Rep.ofSouth

27August202014:30-14:45

GS07Nidufexor，一種非膽汁酸FXR激動劑，在給藥12周后降低NASH患者的ALT水平和肝脂肪分?jǐn)?shù)

GS07Nidufexor,anon-bileacidFXRagonist,decreasesALTandhepaticfatfractioninpatientswithNASHafter12weeksdosing

RichardAspinall,UnitedKingdomCo-author:MichaelBadman

27August202014:45-15:00

GS08在初級保健中引入"reflex"AST檢測可提高晚期肝病的檢出率：TheGwentASTProject（GAP）

GS08Introductionof"reflex"ASTtestinginprimarycareincreasesdetectionofadvancedliverdisease:TheGwentASTProject(GAP)

AndrewYeoman,UnitedKingdomCo-author:Dr.FidanYousuf

28August202013:30-13:45

GS09單酰甘油脂肪酶重組巨噬細(xì)胞和肝細(xì)胞的脂質(zhì)代謝，促進(jìn)肝再生

GS09Monoacylglycerollipasereprogrammeslipidmetabolisminmacrophagesandhepatocytestopromoteliverregeneration

ManonAllaire,FranceCo-author:HélèneGilgenkrantz

28August202013:45-14:00

GS10在接受核苷類似物治療的慢性乙型肝炎患者中，用RNA干擾療法（JNJ-3989）進(jìn)行短期治療可持續(xù)抑制乙型肝炎表面抗原

GS10Short-termtreatmentwithRNAinterferencetherapy,JNJ-3989,resultsinsustainedhepatitisBsurfaceantigensuppressioninpatientswithchronichepatitisBreceivingnucleos(t)ideanaloguetreatment

EdwardGane,NewZealandCo-author:StephenLocarnini

28August202014:00-14:15

GS11巨噬細(xì)胞清道夫受體1介導(dǎo)肥胖相關(guān)非酒精性脂肪肝的脂質(zhì)性炎癥反應(yīng)

GS11MacrophageScavengerReceptor1mediateslipid-inducedinflammationinhumanobesity-relatednon-alcoholicfattyliverdisease

OlivierGovaere,UnitedKingdomCo-author:QuentinAnstee

28August202014:15-14:30

GS12自身免疫性肝炎肝移植術(shù)后患者和移植物的長期存活率

GS12Long-termpatientandgraftsurvivalafterlivertransplantationforautoimmunehepatitis

MelinaHeinemann,GermanyCo-author:ChristophSchramm

28August202014:30-14:45

GS13HCV消除后肝硬化患者血清常規(guī)參數(shù)和AFP演變的分析，用于HCC風(fēng)險分層：來自ANRSCO12CirVir隊(duì)列的軌跡聚群分析

GS13ProfilingofRoutineserumparametersandAFPevolutionincirrhosisfollowingHCVeradicationforstratificationofHCCrisk:atrajectoryclusteringanalysisfromtheANRSCO12CirVircohort

PierreNahon,FranceCo-author:EtienneAudureau

28August202014:45-15:00

信源：ESAL官網(wǎng)